دورية أكاديمية
أعرض في EDS

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.

التفاصيل البيبلوغرافية
العنوان: Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.
المؤلفون: Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes A, Lutrick K, Kuntz JL, Dunnigan K, Odean MJ, Hegmann KT, Stefanski E, Edwards LJ, Schaefer-Solle N, Grant L, Ellingson K, Groom HC, Zunie T, Thiese MS, Ivacic L, Wesley MG, Lamberte JM, Sun X, Smith ME, Phillips AL, Groover KD, Yoo YM, Gerald J, Brown RT, Herring MK, Joseph G, Beitel S, Morrill TC, Mak J, Rivers P, Harris KM, Hunt DR, Arvay ML, Kutty P, Fry AM, Gaglani M
المصدر: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2021 Apr 02; Vol. 70 (13), pp. 495-500. Date of Electronic Publication: 2021 Apr 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE
أسماء مطبوعة: Publication: Atlanta, GA : U.S. Centers for Disease Control
Original Publication: [Atlanta] U. S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control.
مواضيع طبية MeSH: Emergency Responders*/statistics & numerical data , Health Personnel*/statistics & numerical data, COVID-19/*prevention & control , COVID-19 Vaccines/*immunology , Occupational Diseases/*prevention & control , Occupations/*classification, Adolescent ; Adult ; BNT162 Vaccine ; COVID-19/epidemiology ; COVID-19 Nucleic Acid Testing ; COVID-19 Vaccines/administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; United States/epidemiology ; Vaccines, Synthetic/immunology ; Young Adult ; mRNA Vaccines
مستخلص: Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic COVID-19 in randomized placebo-controlled Phase III trials (1,2); however, the benefits of these vaccines for preventing asymptomatic and symptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered in real-world conditions, is less well understood. Using prospective cohorts of health care personnel, first responders, and other essential and frontline workers* in eight U.S. locations during December 14, 2020-March 13, 2021, CDC routinely tested for SARS-CoV-2 infections every week regardless of symptom status and at the onset of symptoms consistent with COVID-19-associated illness. Among 3,950 participants with no previous laboratory documentation of SARS-CoV-2 infection, 2,479 (62.8%) received both recommended mRNA doses and 477 (12.1%) received only one dose of mRNA vaccine. † Among unvaccinated participants, 1.38 SARS-CoV-2 infections were confirmed by reverse transcription-polymerase chain reaction (RT-PCR) per 1,000 person-days. § In contrast, among fully immunized (≥14 days after second dose) persons, 0.04 infections per 1,000 person-days were reported, and among partially immunized (≥14 days after first dose and before second dose) persons, 0.19 infections per 1,000 person-days were reported. Estimated mRNA vaccine effectiveness for prevention of infection, adjusted for study site, was 90% for full immunization and 80% for partial immunization. These findings indicate that authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection, regardless of symptom status, among working-age adults in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.
Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Allison L. Naleway reported funding from Pfizer for a meningococcal B vaccine study unrelated to the submitted work. Kurt T. Hegmann serves at the Editor of the American College of Occupational and Environmental Medicine’s evidence-based practice guidelines. Matthew S. Thiese reported grants and personal fees from Reed Group and the American College of Occupational and Environmental Medicine, outside the submitted work. No other potential conflicts of interest were disclosed.
التعليقات: Comment in: N Engl J Med. 2021 Sep 30;385(14):1336-1337. (PMID: 34525278)
References: JAMA Netw Open. 2020 Jul 1;3(7):e2016382. (PMID: 32697321)
N Engl J Med. 2021 Apr 22;384(16):1576-1577. (PMID: 33596348)
N Engl J Med. 2021 May 20;384(20):1962-1963. (PMID: 33755374)
Lancet. 2021 May 8;397(10286):1725-1735. (PMID: 33901423)
Med. 2021 Aug 13;2(8):979-992.e8. (PMID: 34223401)
N Engl J Med. 2021 May 6;384(18):1774-1775. (PMID: 33755376)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Lancet. 2021 Mar 6;397(10277):875-877. (PMID: 33610193)
J Assoc Med Microbiol Infect Dis Can. 2020 Dec 31;5(4):223-234. (PMID: 36340059)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
المشرفين على المادة: 0 (COVID-19 Vaccines)
0 (Vaccines, Synthetic)
N38TVC63NU (BNT162 Vaccine)
تواريخ الأحداث: Date Created: 20210401 Date Completed: 20210402 Latest Revision: 20231213
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8022879
DOI: 10.15585/mmwr.mm7013e3
PMID: 33793460
قاعدة البيانات: MEDLINE
الوصف
تدمد:1545-861X
DOI:10.15585/mmwr.mm7013e3